Faculty Opinions recommendation of Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Authors
Publication date
28 February 2017
Publisher
Faculty Opinions Ltd
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.3410%2Ff.727191509...
      Last time updated on 11/08/2021